| CAS NO: | 891859-12-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight | 435.56 |
|---|---|
| Formula | C27H33NO4 |
| CAS No. | 891859-12-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mM |
| Water: N/A | |
| Ethanol: N/A | |
| Chemical Name | 1-((6-((2-methoxy-4-propylbenzyl)oxy)-1-methyl-3,4-dihydronaphthalen-2-yl)methyl)azetidine-3-carboxylic acid |
| Synonyms | ONO-4641; ONO 4641; ONO4641 |
| In Vitro | In vitro activity: Ceralifimod (also known as ONO-4641) is a novel sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Kinase Assay: Ceralifimod (also known as ONO-4641) is a novel sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5. Cell Assay: |
|---|---|
| In Vivo | Ceralifimod is used as a clinical candidate that exhibited>30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing). |
| Animal model | Mice |
| Formulation & Dosage | |
| References | J Med Chem. 2017 Dec 14;60(23):9508-9530; J Clin Pharmacol. 2015 Sep;55(9):1051-60. |
m.cnreagent.com